A review article has been published in the journal Current Pharmaceutical Design which provides an overview of the recent literature discussing the different clinical forms of heart disease resulting from virus infections including the prognosis, and current therapies. Many common viruses causing respiratory illness, including enteroviruses and influenza viruses among others, have the potential to infect the heart and initiate an immune response to the infection. These viruses can also produce mild to lethal cardiac injury.
This is a photomicrograph of normal heart muscle. Courtesy of Dr. Sally Huber
A review article has been published in the journal Current Pharmaceutical Design which provides an overview of the recent literature discussing the different clinical forms of heart disease resulting from virus infections including the prognosis, and current therapies. Many common viruses causing respiratory illness, including enteroviruses and influenza viruses among others, have the potential to infect the heart and initiate an immune response to the infection. These viruses can also produce mild to lethal cardiac injury.
Viral myocarditis is a leading cause of sudden unexpected death from cardiovascular causes primarily in men who are less than 40 years in age. Women either have a lower incidence of viral myocarditis or develop less severe infection than men. The infection can exist as an acute and self-limiting form (fulminant myocarditis) in which patients usually recover once the virus is cleared. However, patients with severely compromised cardiac function may require temporary use of a left ventricular assist device. Other patients develop chronic myocarditis, a progressive inflammation of the heart muscle, which results either from the establishment of persistent virus infections that the body cannot eliminate or the induction of autoimmunity to heart proteins. Chronic myocarditis lasting many months and years ultimately results in dilated cardiomyopathy which may require heart transplantation. It is estimated that up to 30 percent of allclinical dilated cardiomyopathy cases result from underlying viral infections.
Experimental animal models have been used to investigate many aspects of the clinical disease such as the sex bias in myocarditis where testosterones in males promote autoimmunity in the heart while estrogens in females suppress virus infection and autoimmunity. Knowledge from animal studies is now being applied to the clinical disease and this should lead to improved diagnosis and therapy.
Source: Bentham Science Publishers
Avian Flu Risks in Veterinary Practice: Protecting Those on the Frontlines
January 6th 2025Veterinarians, technicians, and veterinarian infection preventionists face risks from H5N1 avian flu when handling farm animals or exposed wildlife. Learn key prevention strategies, PPE recommendations, and emerging challenges.
Understanding the True Threat: Richard Webby, PhD, on H5N1 Avian Flu and Its Human Impact
January 3rd 2025Richard Webby, PhD, the director of the World Health Organization (WHO) Collaborating Centre or Studies on the Ecology of Influenza in Animals and Birds, discusses the evolving dynamics of H5N1 avian flu, its variants, and the low risk to humans while emphasizing vigilance among health care professionals.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.